Cargando…

Comparison of Microbiological, Histological, and Immunomodulatory Parameters in Response to Treatment with Either Combination Therapy with Prednisone and Metronidazole or Probiotic VSL#3 Strains in Dogs with Idiopathic Inflammatory Bowel Disease

BACKGROUND: Idiopathic inflammatory bowel disease (IBD) is a common chronic enteropathy in dogs. There are no published studies regarding the use of probiotics in the treatment of canine IBD. The objectives were to compare responses to treatment with either combination therapy (prednisone and metron...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rossi, Giacomo, Pengo, Graziano, Caldin, Marco, Palumbo Piccionello, Angela, Steiner, Jörg M., Cohen, Noah D., Jergens, Albert E., Suchodolski, Jan S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983225/ https://www.ncbi.nlm.nih.gov/pubmed/24722235 http://dx.doi.org/10.1371/journal.pone.0094699

Ejemplares similares

Development of omics‐based protocols for the microbiological characterization of multi‐strain formulations marketed as probiotics: the case of VSL#3
por: Mora, Diego, et al.
Publicado: (2019)

Fecal Microbial and Metabolic Profiles in Dogs With Acute Diarrhea Receiving Either Fecal Microbiota Transplantation or Oral Metronidazole
por: Chaitman, Jennifer, et al.
Publicado: (2020)

Comparative genomic analysis of the multispecies probiotic-marketed product VSL#3
por: Douillard, François P., et al.
Publicado: (2018)

Correction: Comparative genomic analysis of the multispecies probiotic-marketed product VSL#3
por: Douillard, François P., et al.
Publicado: (2018)

Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases
por: Cheng, Fang-Shu, et al.
Publicado: (2020)

Probiotic Therapy With VSL#3(®) in Patients With NAFLD: A Randomized Clinical Trial
por: Derosa, Giuseppe, et al.
Publicado: (2022)

Corrigendum to “Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases”
por: Sang, Li-Xuan
Publicado: (2021)

Probiotic colonization dynamics after oral consumption of VSL#3(®) by antibiotic-treated mice
por: Theriot, Casey, et al.
Publicado: (2022)

Probiotics (VSL#3) Prevent Endothelial Dysfunction in Rats with Portal Hypertension: Role of the Angiotensin System
por: Rashid, Sherzad K., et al.
Publicado: (2014)

Amelioration of intestinal and systemic sequelae of murine Campylobacter jejuni infection by probiotic VSL#3 treatment
por: Ekmekciu, Ira, et al.
Publicado: (2017)

Clinicopathologic and gastrointestinal effects of administration of prednisone, prednisone with omeprazole, or prednisone with probiotics to dogs: A double‐blind randomized trial
por: Rak, Mariola B., et al.
Publicado: (2023)

The Probiotic Mixture VSL#3 Accelerates Gastric Ulcer Healing by Stimulating Vascular Endothelial Growth Factor
por: Dharmani, Poonam, et al.
Publicado: (2013)

PReS-FINAL-2074: The role of the probiotic VSL-3 as adjuvant therapy in patients with undifferentiated spondyloarthritis (ERA)
por: Vidovic, M, et al.
Publicado: (2013)

Correction: Probiotics (VSL#3) Prevent Endothelial Dysfunction in Rats with Portal Hypertension: Role of the Angiotensin System
Publicado: (2014)

Chronic bacterial prostatitis and irritable bowel syndrome: effectiveness of treatment with rifaximin followed by the probiotic VSL#3
por: Vicari, Enzo, et al.
Publicado: (2014)

Probiotics VSL#3 Protect against Development of Visceral Pain in Murine Model of Irritable Bowel Syndrome
por: Distrutti, Eleonora, et al.
Publicado: (2013)

VSL#3 probiotic modifies mucosal microbial composition but does not reduce colitis-associated colorectal cancer
por: Arthur, Janelle C., et al.
Publicado: (2013)

Change of Fecal Flora and Effectiveness of the Short-term VSL#3 Probiotic Treatment in Patients With Functional Constipation
por: Kim, Seong-Eun, et al.
Publicado: (2015)

The Epithelial Barrier Model Shows That the Properties of VSL#3 Depend from Where it is Manufactured
por: Palumbo, Paola, et al.
Publicado: (2019)

Probiotic VSL#3 Treatment Reduces Colonic Permeability and Abdominal Pain Symptoms in Patients With Irritable Bowel Syndrome
por: Boonma, Prapaporn, et al.
Publicado: (2021)

Correction: The Probiotic Mixture VSL#3 Accelerates Gastric Ulcer Healing by Stimulating Vascular Endothelial Growth Factor
por: Dharmani, Poonam, et al.
Publicado: (2022)

Modulation of Intestinal Microbiota by the Probiotic VSL#3 Resets Brain Gene Expression and Ameliorates the Age-Related Deficit in LTP
por: Distrutti, Eleonora, et al.
Publicado: (2014)

Role of probiotics VSL#3 in prevention of suspected sepsis in low birthweight infants in India: a randomised controlled trial
por: Sinha, Anju, et al.
Publicado: (2015)

Probiotic mixture VSL#3 reduce high fat diet induced vascular inflammation and atherosclerosis in ApoE(−/−) mice
por: Chan, Yee Kwan, et al.
Publicado: (2016)

The Probiotic Compound VSL#3 Modulates Mucosal, Peripheral, and Systemic Immunity Following Murine Broad-Spectrum Antibiotic Treatment
por: Ekmekciu, Ira, et al.
Publicado: (2017)

Effects of the Probiotic Mixture Slab51® (SivoMixx®) as Food Supplement in Healthy Dogs: Evaluation of Fecal Microbiota, Clinical Parameters and Immune Function
por: Rossi, Giacomo, et al.
Publicado: (2020)

The cecal and fecal microbiomes and metabolomes of horses before and after metronidazole administration
por: Arnold, Carolyn E., et al.
Publicado: (2020)

Rapid Resolution of Large Bowel Diarrhea after the Administration of a Combination of a High-Fiber Diet and a Probiotic Mixture in 30 Dogs
por: Rossi, Giacomo, et al.
Publicado: (2020)

The Probiotic Mixture VSL#3 Dampens LPS-Induced Chemokine Expression in Human Dendritic Cells by Inhibition of STAT-1 Phosphorylation
por: Mariman, Rob, et al.
Publicado: (2014)

The Probiotic Mixture VSL#3 Alters the Morphology and Secretion Profile of Both Polarized and Unpolarized Human Macrophages in a Polarization-Dependent Manner
por: Isidro, Raymond A., et al.
Publicado: (2014)

Assessing the efficacy and safety of fecal microbiota transplantation and probiotic VSL#3 for active ulcerative colitis: A systematic review and meta-analysis
por: Dang, Xiaofei, et al.
Publicado: (2020)

Probiotic mixture VSL#3 prevents ulcerative colitis-associated carcinogenesis in mice and cells by regulating the inflammatory and Wnt/β-catenin pathway
por: Li, Wenbin, et al.
Publicado: (2022)

Effects of metronidazole on the fecal microbiome and metabolome in healthy dogs
por: Pilla, Rachel, et al.
Publicado: (2020)

Effect of a probiotic preparation (VSL#3) in critically ill patients: A randomized, double-blind, placebo-controlled trial (Pilot Study)
por: Ebrahimi-Mameghani, Mehrangiz, et al.
Publicado: (2013)

Oral Probiotic VSL#3 Prevents Autoimmune Diabetes by Modulating Microbiota and Promoting Indoleamine 2,3-Dioxygenase-Enriched Tolerogenic Intestinal Environment
por: Dolpady, Jayashree, et al.
Publicado: (2016)

A randomised placebo controlled trial of VSL#3(®) probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease
por: Chong, Pui Lin, et al.
Publicado: (2021)

VSL#3 can prevent ulcerative colitis-associated carcinogenesis in mice
por: Wang, Chun-Sai-Er, et al.
Publicado: (2018)

Microbiological Testing of Probiotic Preparations
por: Zawistowska-Rojek, Anna, et al.
Publicado: (2022)

Symptom Severity Following Rifaximin and the Probiotic VSL#3 in Patients with Chronic Pelvic Pain Syndrome (Due to Inflammatory Prostatitis) Plus Irritable Bowel Syndrome
por: Vicari, Enzo, et al.
Publicado: (2017)

Mechanism of Probiotic VSL#3 Inhibiting NF-κB and TNF-α on Colitis through TLR4-NF-κB Signal Pathway
por: WANG, Hui, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_d51c377s50s4ec20msqe7bd86g